This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mullin, S.
Right arrow Articles by Murphy, C. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mullin, S.
Right arrow Articles by Murphy, C. K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2006, p. 1908-1909, Vol. 50, No. 5
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.5.1908-1909.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Activity of Novel Benzoxazinorifamycins against Rifamycin-Resistant Streptococcus pyogenes


arrow
LETTER
 
Serious gram-positive infections are frequently caused by Staphylococcus aureus or Streptococcus pyogenes. The rifamycin rifampin (RIF) is often used as part of the treatment for such infections, because it has potent bactericidal activity against both free-living and biofilm-associated gram-positive bacteria (13) and has favorable pharmacokinetics (2). Despite this, RIF's use as monotherapy has been limited because of treatment failure due to the emergence of rifamycin-resistant organisms (3, 4, 7, 8). Resistance results from amino acid substitutions within the conserved rifamycin resistance-determining region (RRDR) of the RpoB subunit of RNA polymerase, the target of rifamycins. Because of resistance emergence, RIF is used mainly as part of a multidrug treatment regimen in which the partner drug(s) is able to prevent outgrowth of resistant subpopulations.

A previous study described the activity of the benzoxazinorifamycins rifalazil (RFZ) and related new chemical entities (NCEs) against RIF-resistant S. aureus (10). The maximum MICs of the most potent NCEs were 2 to 4 µg/ml against the most rifamycin-resistant S. aureus strains. RIF and RFZ have MICs of >512 µg/ml against these same strains (10). Considering that a large proportion of serious gram-positive infections are caused by streptococci, we sought to determine in the present study whether NCEs had improved activity against rifamycin-resistant strains of S. pyogenes.

The two mutations conferring RIF resistance in clinical isolates of S. pyogenes (4, 7) and several mutations in other streptococci (1, 5, 6, 9, 12) all reside in the RRDR of RpoB in these organisms. S. pyogenes ATCC 19615 mutants with decreased susceptibility to RIF were selected for and characterized as described previously (10). The resistance frequencies of S. pyogenes for RIF were 7.0 x 10–8 (at 0.24 µg/ml), 6.0 x 10–8 (at 0.12 µg/ml), and 2.9 x 10–8 (at 0.06 µg/ml). Thirty-three colonies with decreased susceptibility to RIF were isolated, and oligonucleotide primers SPY-F and SPY-R (5'-AACCGTCGTATCCGTGCCGTTGGT-3' and 5'-TGCCGTCGCAACAGCAACTACCTG-3', respectively) were used to amplify and DNA sequence their RRDR regions, encoded by base pairs 1228 to 1884 (S. pyogenes MGAS315 coordinates; GenBank accession number NC 004070).

Seventeen discrete amino acid changes at 10 different positions within the S. pyogenes RRDR were identified (Table 1). Changes at H486, R489, and S491 correspond to positions that, when altered, confer the high levels of resistance to rifamycins in other bacteria (10). The H486N substitution was previously identified in a RIF-resistant clinical strain of S. pyogenes (7).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Susceptibility of S. pyogenes RIF-resistant mutants to RIF, RFZ, and select NCEs

The MICs of RIF, RFZ, and NCEs for S. pyogenes ATCC 19615 and its rifamycin-resistant derivatives were determined using standard methods (11). S. pyogenes ATCC 19615 was 16- to 32-fold more susceptible to RFZ and NCEs than was S. aureus ATCC 29213 (Table 1) (10). MICs of the most potent NCEs (e.g., ABI-0043) against rifamycin-resistant S. pyogenes strains ranged from 0.00025 µg/ml to 0.25 µg/ml for the most resistant strain (Table 1) and 0.016 µg/ml to 4 µg/ml for the most rifamycin-resistant S. aureus strains (10). In fact, the MICs of NCEs against S. pyogenes mutants (Table 1) were consistently ≥8-fold lower than those for S. aureus mutants containing mutations in the corresponding codon of the rpoB gene (10).

It is anticipated that NCEs having in vivo efficacy against rifamycin-resistant S. aureus strains would be effective against the most resistant S. pyogenes mutants. Experimental infection models using resistant strains from both of these species should verify this assumption.


arrow
ACKNOWLEDGMENTS
 
We thank Courtney Tanzi-Calabria for technical assistance. DNA sequence analysis was carried out at the Tufts University DNA Sequencing Facility.


arrow
REFERENCES
 
    1
  1. Achour, W., O. Guenni, M. Fines, R. Leclercq, and A. Ben Hassen. 2004. rpoB mutations in Streptococcus mitis clinical isolates resistant to rifampin. Antimicrob. Agents Chemother. 48:2757-2759.[Abstract/Free Full Text]
    2. 2
  2. Acocella, G. 1983. Pharmacokinetics and metabolism of rifampin in humans. Rev. Infect. Dis. 5(Suppl. 3):S428-S432.
    3. 3
  3. Aubry-Damon, H., C. J. Soussy, and P. Courvalin. 1998. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 42:2590-2594.[Abstract/Free Full Text]
    4. 4
  4. Aubry-Damon, H., M. Galimand, G. Gerbaud, and P. Courvalin. 2002. rpoB mutation conferring rifampin resistance in Streptococcus pyogenes. Antimicrob. Agents Chemother. 46:1571-1573.[Abstract/Free Full Text]
    5. 5
  5. Chen, J. Y., C. P. Fung, F. Y. Chang, L. Y. Huang, J. C. Chang, and L. K. Siu. 2004. Mutations of the rpoB gene in rifampicin-resistant Streptococcus pneumoniae in Taiwan. J. Antimicrob. Chemother. 53:375-378.[Abstract/Free Full Text]
    6. 6
  6. Ferrandiz, M. J., C. Ardanuy, J. Linares, J. M. Garcia-Arenzana, E. Cercenado, A. Fleites, A. G. de la Campa, and the Spanish Pneumococcal Infection Study Network. 2005. New mutations and horizontal transfer of rpoB among rifampin-resistant Streptococcus pneumoniae from four Spanish hospitals. Antimicrob. Agents Chemother. 49:2237-2245.[Abstract/Free Full Text]
    7. 7
  7. Herrera, L., C. Salcedo, B. Orden, B. Herranz, R. Martinez, A. Efstratiou, and J. A. Saez Nieto. 2002. Rifampin resistance in Streptococcus pyogenes. Eur. J. Clin. Microbiol. Infect. Dis. 21:411-413.[Medline]
    8. 8
  8. Jacobs, M. R., H. J. Koornhof, R. M. Robins-Browne, C. M. Stevenson, Z. A. Vermaak, I. Freiman, G. B. Miller, M. A. Witcomb, M. Isaacson, J. I. Ward, and R. Austrian. 1978. Emergence of multiply resistant pneumococci. N. Engl. J. Med. 299:735-740.[Abstract]
    9. 9
  9. Meier, P. S., S. Utz, S. Aebi, and K. Muhlemann. 2003. Low-level resistance to rifampin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47:863-868.[Abstract/Free Full Text]
    10. 10
  10. Murphy, C. K., S. Mullin, M. S. Osburne, J. van Duzer, J. Siedlecki, X. Yu, K. Kerstein, M. Cynamon, and D. M. Rothstein. 2006. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50:827-834.[Abstract/Free Full Text]
    11. 11
  11. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A6, vol. 23. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    12. 12
  12. Padayachee, T., and K. P. Klugman. 1999. Molecular basis of rifampin resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:2361-2365.[Abstract/Free Full Text]
    13. 13
  13. Widmer, A. F., R. Frei, Z. Rajacic, and W. Zimmerli. 1990. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J. Infect. Dis. 162:96-102.[Medline]
Steve Mullin
Novartis Institutes for Biomedical Research, Inc., Infectious Disease, Cambridge, MA 02139,1

David M. Rothstein
Christopher K. Murphy*
ActivBiotics, Inc., 110 Hartwell Ave., Lexington, MA 02421,2

* Phone: (781) 372-4821 Fax: (781) 274-9129 E-mail: cmurphy{at}activbiotics.com

Antimicrobial Agents and Chemotherapy, May 2006, p. 1908-1909, Vol. 50, No. 5
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.5.1908-1909.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rothstein, D. M., Farquhar, R. S., Sirokman, K., Sondergaard, K. L., Hazlett, C., Doye, A. A., Gwathmey, J. K., Mullin, S., van Duzer, J., Murphy, C. K. (2006). Efficacy of Novel Rifamycin Derivatives against Rifamycin-Sensitive and -Resistant Staphylococcus aureus Isolates in Murine Models of Infection. Antimicrob. Agents Chemother. 50: 3658-3664 [Abstract] [Full Text]  

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mullin, S.
Right arrow Articles by Murphy, C. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mullin, S.
Right arrow Articles by Murphy, C. K.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»